tbuckley/cabot-search huggingface dataset:
Analysis of patient age and adjuvant chemotherapy (ACh) as predictor of survival in patients (pts) with resected gastric adenocarcinoma (RGA).
Authors: L. Visa, J. J. Grau, M. Caballero, E. Pineda, V. Ortega, L. Gaba, P. Gascon
Journal: Journal of Clinical Oncology (2011)

e14518 Background: ACh and young age are favorable prognostic factrors in RGA. We retrospectively analysed the relationships of both factors in RGA pts. Methods: From 1977 and 2002, 430 consecutive patients with RGA were followed after ACh or after surgery without ACh .The ACh cosisted of mitomycin 10 mg/m2 (MMC) or MMC plus oral Tegafur, 500 mg/m2/day for six months. Grouping of age were 1=under 46 yrs 50 (12%) pts; 2=46 to 54 yrs 61 (14%) pts; 3=55 to 64 yrs 128 (30%) pts; and 4=over 64 yrs 191 (44%) pts. Results: Pts median age: 63 years (range 22-93). Gender, 277 (64%) male and 153 (36%) female. Tumor location was antrum, 186 (43%) pts, body 133 (31%) pts, cardia, 34 (8%) pts and not specified 77 (18%). Staging was node positive 247 (57%) pts or node negative 183 (43%) pts. ACh was given in 236 (55%) pts and did not in other 194 (45%). Median follow-up 76 moths. Significant differences in favor of the first subgroup in univariate analysis were node negative vs positive (p<0.0001); ACh vs no ACh in all pts (p<0.0001) and in group 3 (p<0.0001), group 4 (p=0.0002) and in group 3+4 (p<0.0001); a tendence of female vs male (p=0.0512), and group 4 vs 3 (p=0.0339) and group 1 vs 3 (p=0.0280). In a multivariate Cox analysis including age (over 63 vs less); gender (male vs female); stage (node positive vs negative); ACh global and group 3+4, only nodal stage (OR=3.34, 95% CI: 2.44-4.57, p<0.0001); global ACh (OR=0.38, 95% CI: 0.29-0.51, p<0.0001) and ACh in groups 3+4 (OR=0.31, 95% CI: 0.22-0.44, p<0.0001) were statistically significant. Conclusions: ACh is a predictive factor of favorable outcome in elderly pts with RGA.
Effect of NF-kappaB RelB subunit expression on the biology of prostate cancer cells.
Authors: I. Labouba, A. Poisson, N. Delvoye, A. Mes-Masson, F. Saad
Journal: Journal of Clinical Oncology (2011)

e21052 Background: Our group previously observed the nuclear localization of the alternative NF-kB subunits RelB and p52 in tumor cells of prostate cancer (PCa) patients. These observations, based on immunohistochemistry analyses, suggest a constitutive activation of the alternative NF-kB pathway and a potential implication in PCa progression. The current study aims to define the role of the alternative NF-kB signaling in PCa by focusing on RelB, the alternative NF-kB subunit with a gene expression promoting transactivation domain. We used an over-expression system to assess its effects on the biology of a PCa cell line. Methods: PCa cell lines (LNCaP, 22Rv1, DU145 and PC3) express RelB differentially. Indeed, Western blot analyses clearly show a higher expression of RelB in DU145 and PC3 cells, while LNCaP and 22Rv1 cells do not express it. Using a lentivirus-based expression system, we introduced the cDNA of RelB into the 22Rv1 cells. We then assessed RelB’s effects on different cellular processes such as cell proliferation, migration, adhesion and 3D anchorage-independent cell growth (soft agar assay). Results: By introducing RelB into 22Rv1 cells using lentiviral infection, we induced the expression of RelB at a level comparable to those observed in DU145 and PC3 cell lines. Our results indicate that the expression of RelB doubles the cellular proliferation rate in 22Rv1 cells after 5 days of culture (p<0.05). However, RelB expression decreases the ability of the 22Rv1 cells to grow in 3D (p=0.002). Moreover, RelB over-expression halves the migration rate of 22Rv1 cells (p=0.017), but did not affect their adhesion on a matrix coated with type I collagen (p=0.183). Conclusions: This study reveals that in 22Rv1 cells, over-expression of RelB distinctly modifies proliferation, migration and 3D anchorage-independent growth. Ongoing in vivo experiments will determine how RelB expression affects the tumorigenic potential of 22Rv1 cells, thereby providing clues to its possible role in PCa.
Prostate cancer detection rates of negative MP-MRIs.
Authors: Amanda Lu, Cayce Nawaf, Jeffrey Weinreb, James Rosoff, Peter Schulam, Peter Humphrey, Angelique Levi, Preston Sprenkle
Journal: Journal of Clinical Oncology (2016)

91 Background: Increased lesion suspicion score on MRI is known to be associated with increased grade of prostate cancer. However, the negative predictive value (NPV) of MRI is still being investigated. To determine the NPV of mpMRI, we evaluated the frequency of prostate cancer (CaP) detection by 12-core template mapping biopsy (Mbx) in men whose mpMRI showed no suspicious regions. Methods: 374 men undergoing MRI-US fusion biopsy from 12/2012 to 06/2015 were enrolled in an IRB-approved database and met inclusion criteria for this study. The mpMRI sequences T2-weighted, diffusion-weighted imaging, and dynamic contrast enhancement were used to identify and classify targets as low, medium, and high suspicion. Men with negative mpMRI received a template 12-core template mapping biopsy. Only patients with complete mpMRI sequences were included. Results: 53 men with a negative MRI were identified (mean age=63.5 years, PSA=7.53 ng/mL, mean prostate volume=67.2 mL). The NPV of negative MRI was 64.2% for any cancer and 96.2% for clinically significant cancer (Gleason≥7). Men on active surveillance had the highest CDR 56.3%, compared to 38.9% for biopsy-naive men, and 15.8% for men with prior negative biopsy (Figure 1). Clinically significant CaP was found in two patients: Gleason 4+3 in a patient on Active Surveillance, and 4+4 in a biopsy naïve patient. Conclusions: Negative MRI has a high NPV (96%) for clinically significant CaP found in 12-core template mapping biopsy. If we did not biopsy mpMRI negative men, we would have missed 16 patients with Gleason 6 and 2 patients with ≥ Gleason 7. Clinicians can use this information in patient counseling to discuss the likelihood of detecting significant cancer – though these findings should be reproduced widely before a negative MRI is used to recommend against biopsy. Sources of funding: NIH-National Institute of Diabetes and Digestive and Kidney Diseases [Table: see text]
Angiopoietin-1 Supports SRC Activity Acquisition of Human CD34-Bone Marrow Cells.
Authors: Kiyoshi Ando, Yoshihiko Nakamura, Takashi Yahata, Yukari Muguruma, Tadayuki Sato, Hideyuki Matsuzawa, Tomoko Uno, Shunichi Kato, Tomomitsu Hotta
Journal: Blood (2006)
COCIS individual patient data (IPD) meta-analysis: Carboplatin- or cisplatin-based chemotherapy (CT) as first-line treatment of small cell lung cancer (SCLC).
Authors: A. Rossi, M. Di Maio, P. Chiodini, R. Rudd, H. Okamoto, D. Skarlos, M. Frueh, W. Qian, T. Tamura, E. Samantas, T. Shibata, F. Perrone, C. Gallo, C. Gridelli, O. Martelli, S. M. Lee
Journal: Journal of Clinical Oncology (2011)

7022 Background: Selecting carboplatin or cisplatin in the treatment of poor prognosis and/or extensive stage SCLC remains controversial. We performed an IPD meta-analysis from published randomized trials. Methods: In June 2009, a systematic review was performed to identify randomized phase III trials comparing cisplatin- vs. carboplatin-based CT in the first-line treatment of SCLC. Primary endpoint of the meta-analysis was overall survival (OS). IPD (baseline characteristics, treatment details, toxicity and outcome measures) were obtained via collaborating with all groups identified by the systematic review. All statistical analyses were stratified by trials. OS and progression-free survival (PFS) curves were compared using the log-rank test. Response rate was compared using the Mantel-Haenszel test. Results: All four eligible trials were included in the analysis with a total of 663 patients (329 cisplatin, 334 carboplatin). Baseline characteristics were well balanced between arms. Median age was 67 years (27-86). Performance status (PS) was 0-1 in 72%, 2-3 in 28%; 68% of patients had extensive stage. With 589 deaths recorded (89%), median OS was 9.5 months with cisplatin, and 9.5 months with carboplatin (hazard ratio [HR] carboplatin vs. cisplatin 1.03, 95% confidence interval [CI] 0.88–1.22; p = 0.69). There was no evidence of treatment difference between cisplatin and carboplatin according to different gender, stage, PS or age. Response rate was 67.5% and 65.6%, with cisplatin and carboplatin, respectively (relative risk 0.96, 95% CI 0.82-1.13; p = 0.66). Median PFS was 5.3 and 5.5 months, for cisplatin and carboplatin, respectively (HR 1.01, 95% CI 0.86–1.19; p = 0.90). Toxicity profile was significantly different: hematological toxicity was higher with carboplatin, and non-hematologic toxicity higher with cisplatin. Conclusions: COCIS is the first IPD meta-analysis in the treatment of poor prognosis and/or extensive stage SCLC. We found no survival difference between cisplatin- and carboplatin-based CT but a different toxicity profile was reported.
Frequency of UGT1A1*28 gene polymorphism in Chinese gastrointestinal cancer patients and its relationship with irinotecan-related diarrhea.
Authors: Y. Su, T. Ma, Z. b. Ye, J. Zhang, Z. G. Zhu
Journal: Journal of Clinical Oncology (2011)

451 Background: The incidence of irinotecan-related adverse events was associated with the polymorphism of uridine diphosphate glucuronosyltransferases (UGTs) gene, and demonstrated as obvious ethnic diversity. The aim of this study is to observe the frequency and severity of various adverse events in Han patients with advanced gastrointestinal cancer who was treated with irinotecan-based therapy. Simultaneously, the relationship between the severe adverse events and UGT1A1 gene promoter polymorphism (UGT1A1*28) was investigated. Methods: A total of 109 patients (65 men and 44 women; median 57 years; range: 34-76 years) with advanced gastrointestinal carcinoma receiving irinotecan-based chemotherapy were enrolled. The adverse events during the course chemotherapy, the pretreatment serum bilirubin level, as well as the time to the Grade 3-4 toxicities occurrence were recorded. Genomic DNA was extracted from the peripheral blood to detect the polymorphism of UGT1A1*28 (TATA box thymine-adenine TA repeats). The relationship between the severity of adverse events and UGT1A1*28 polymorphism was investigated. Results: Of all these 109 enrolled patients, 90 patients were identified with thymine-adenine (TA) 6 /(TA) 6 genotype, 19 patients with the thymine-adenine (TA) 6 /(TA) 7 genotype, and no (TA) 7 /(TA) 7 genotype was found. Forty-six and 12 patients developed grade 3-4 neutropenia, while 8 and 5 patients occurred grade 3-4 diarrhea in (TA) 6 /(TA) 6 group and (TA) 6 /(TA) 7 group, respectively. The occurrence of grade 3-4 diarrhea but not neutropenia was closely related with (TA) 6 /(TA) 7 genotype in UGT1A1 promoter region in patients receiving irinotecan-based chemotherapy (P=0.033). Conclusions: The frequency of UGT1A1*28 gene polymorphism in Han patients is 17.4%, which is lower than that reported in western populations. The marked increase in grade 3-4 diarrhea is related with (TA) 6 /(TA) 7 genotype of UGT1A1 in patients receiving irinotecan-based chemotherapy. [Table: see text]
Neoadjuvant therapy for pancreatic cancer in patients older than age 75.
Authors: John Thomas Miura, Ashley N Krepline, Kaleb D Duelge, Ben George, Paul S. Ritch, Beth Erickson, James P. Thomas, Anna Mahmoud, Edward J Quebbeman, Kiran Turaga, Fabian McCartney Johnston, Kathleen K. Christians, T. Clark Gamblin, Douglas B. Evans, Susan Tsai
Journal: Journal of Clinical Oncology (2014)

287 Background: Multiple treatments in series may be difficult for older patients (pt) to tolerate. We sought to examine the outcomes associated with neoadjuvant therapy in older pt with resectable (R) or borderline resectable (BLR) pancreatic cancer (PC). Methods: Pt ≥75 years (O) with those &lt;75 (Y) with R or BLR PC receiving neoadjuvant therapy from 2008-2012 were identified. Clinicopathologic and treatment data were abstracted. Completion of all therapy was defined as the receipt of neoadjuvant therapy followed by surgical resection. Results: We identified 77 (42.5%) R and 104 (57.5%) BLR pt; 29 (16%) were ≥ 75 years. Higher Charlson Comorbidity Index (CCI) (median CCI 4 vs. 2, p&lt;0.01) and more hospitalizations during neoadjuvant therapy (50% vs. 28%, p=0.04) were associated with O vs. Y pt. Older pt were less likely to complete all therapy as compared to Y pt (72.4 vs. 89.5%, p&lt;0.01). Poor performance status was the most common reason for failure to complete all therapy in O vs. Y pt (17.2% vs. 0.7%; p&lt;0.01). Higher CCI (OR 0.25; 95% CI: 0.08-0.74, p=0.01) and higher clinical stage (OR 0.17; 95%CI: 0.06-0.48, p&lt;0.01) were associated with failure to complete all therapy. Of the 138 pt that completed all therapy, no significant differences in complication rates (15 vs. 15.3%, p=0.33), median length of hospital stay (10 vs. 9 days, p=0.29), 30 day readmission rates (10 vs. 11.9%, p=0.81), or median overall survival (24.3 mo vs. 36.7 mo, p=0.20) were observed between O vs. Y pt. Conclusions: After neoadjuvant therapy, 25% of pt ≥ 75 years of age will not undergo surgical resection. The most common reason for not completing all therapy is a decline in performance status. Whether neoadjuvant therapy improves the selection of older pts who should not undergo an operation or prevents successful resection of pt who may have tolerated an operation is unclear. With evolving paradigms of treatment sequencing, the management of PC pt with advanced age will require further assessment.
Leveraging web-based interface systems with institutional databases to improve compliance with survivorship care plans.
Authors: Katherine Ramsey Gilmore, Patricia Chapman, David Cleveland, Paula A. Lewis-Patterson, Guadalupe R. Palos, Maria Alma Rodriguez
Journal: Journal of Clinical Oncology (2016)

161 Background: ASCO’s Clinical Oncology Clinical Expert Statement on Cancer Survivorship Planning addressed the importance of using survivorship care plans (SCPs) to improve survivors’ care. Evolving information technology strategies, such as web-based systems, offer real-time reporting tools to track providers’ adherence for completion of SCPs. Our abstract reports on the creation of a web-based system to monitor survivors’ care. Methods: Ongoing audits of SCPs indicated broad variation in compliance rates with SCPs. The institutional benchmark for compliance was set at 90%. Yet, FY 2014 rates ranged from 7-97%, X= 84%. To address low or non-compliance rates, our institution selected a commercially available system as the IT intervention to improve compliance with SCPs. Core metrics identified were arrived appointments, missed appointments, completed SCPs, and transitions to survivorship status. To collect data, we used existing institutional databases with information on medical health, scheduled appointments, and other clinical documentation tools were used to collect data. Descriptive statistics were used to analyze and present data. Results: The current design of the Survivorship Performance Scorecard provided a centralized system for reporting data from 11 survivorship clinics. An exploratory review found 18 Passport templates across the 11 clinics, 188 OrderSets, and 986 scheduling codes were used in planning survivorship clinical services. Procedures for patient transition to survivorship clinics were defined in OrderSets, which were reviewed to identify appropriate fields for inclusion in the report. To ascertain compliance, procedures were developed to link arrived appointments with completed SCPs. Final reports will display all metrics by clinic, provider, and other patient level data. After the system goes live in late 2015, the systems benefits and shortfalls will be analyzed. Conclusions: This evolving tool offers a practice-based method for collecting data elements to monitor compliance with SCPs’ completion standards. Future work will focus on designing an alert system to inform providers when compliance rates are below the 90% compliance benchmark.
Outcome of Allogeneic Stem Cell Transplantation for Patients with Chronic Myelofibrosis and Blastic Transformation of Myelofibrosis
Authors: Maria J. Nieto, Eileen Scigliano, Celia L. Grosskreutz, Steven Fruchtman, John Mascarenhas, Keren Osman, Adriana Malone, Samuel Cytryn, Vesna Najfeld, Ronald Hoffman, Luis Isola
Journal: Blood (2011)
CD5+ Chronic B-Cell Lymphoproliferative Disorders Could Contain a Novel Disease Entity.
Authors: Roxana S Dronca, Curtis A. Hanson, Dragan Jevremovic, C. Scott Collins, Kari Rabe, Jessica Sonbert, Susan L. Slager, Susan Schwager, Tait D. Shanafelt, Neil E. Kay, Clive S. Zent
Journal: Blood (2008)
Effects of adjuvant chemotherapy on fatigue and cognitive function.
Authors: H. C. F. Moore, G. H. Yue, M. Parsons, L. A. Rybicki, V. Siemionow
Journal: Journal of Clinical Oncology (2011)

e19533 Background: Understanding of fatigue and cognitive dysfunction, common complaints with chemotherapy (CT), is often limited by lack of baseline assessments, appropriate controls and correlative neurophysiologic (NP) measurements. This pilot study seeks a means to assess physical and mental fatigue associated with CT for breast cancer (BC). Methods: Patients undergoing CT for early BC and age-similar controls underwent NP assessment at baseline, during CT (after 3-4 cycles), and at one year. Testing at each time point included a brief fatigue inventory (BFI), brief mental fatigue assessment (BMF), cognitive testing including Digit Symbol Coding (DS) and Symbol Search (SS) subtests of the Wechsler Adult Intelligence Scale as well as a physical task requiring sustained elbow flexion with assessment of endurance time and perceived effort. Electroencephalogram (EEG) and surface electromyogram (EMG) recordings were obtained during the cognitive and physical tasks respectively. Data were analyzed using repeated measures analysis of variance. Results: Eight pairs completed the first two evaluations and 7 pairs completed all 3 (1 pair withdrawn due to second malignancy). BFI scores demonstrate a trend toward greater fatigue in patients than controls at baseline (p=0.08). BFI is significantly greater for patients during CT (p<0.001) and remains greater at 1 year (p=0.016). BFI is also greater among patients during CT than at baseline (p=0.037). Physical endurance and perception of effort do not change significantly in either group at the different time points. Subjective mental fatigue, measured by BMF, is similar for the two groups at baseline; BMF scores increase significantly during CT for patients relative to controls (p=0.033) but recover to no difference at one year. Objective cognitive function measured by Processing Speed Index (incorporating DS and SS results) remains stable at all three time points for both groups. Conclusions: CT is associated with significant changes in subjective physical and mental fatigue, while objective performance on physical and mental tasks is relatively preserved. Mental fatigue improved by one year, but perception of physical fatigue persisted. EEG and EMG analyses are under way.
Natural history and outcomes in a population-based cohort of synchronous and metachronous colorectal cancers (CRC).
Authors: Jackson Chu, Ozge Goktepe, Winson Y. Cheung
Journal: Journal of Clinical Oncology (2013)

485 Background: Early data suggest that synchronous and metachronous CRC may portend a worse prognosis when compared to solitary CRC. Our study objectives were to 1) characterize the clinical features and treatment patterns of synchronous and metachronous CRC and 2) compare their survival outcomes with those of solitary CRC. Methods: All patients diagnosed with either synchronous or metachronous CRC between 1999 and 2008 and referred to 1 of 5 regional cancer centers in British Columbia were reviewed. Synchronous and metachronous CRC were defined as multiple (2 or more) distinct tumors that were diagnosed within and beyond 6 months of the date of index CRC diagnosis, respectively. Patients with liver metastases at initial diagnosis were excluded. Kaplan-Meier and multivariate Cox regression analyses were used to estimate survival for synchronous and metachronous CRC, and to compare outcomes with solitary CRC. Results: A total of 213 patients with 388 synchronous and 69 metachronous cases of CRC were included: median age was 70 (range 26-94), 55% were men, and 30% were ECOG 0 to 1 at index diagnosis. At initial presentaiton, 35% and 51% of patients who manifested with synchronous and metachronous tumors, respectively, were TNM stage III. Concurrent colorectal adenomas were found in 45% of synchronous and 33% of metachronous cases. The most prevalent symptoms experienced by patients included changes in bowel movements and abdominal pain. The majority of patients underwent a curative resection (99% of synchronous and 97% of metachronous). Adjuvant chemotherapy was used to treat 44% of both synchronous and metachronous tumors. Compared to solitary CRC, patients with synchronous and metachronous CRC had similar 3-year relapse-free survival (66 vs. 66 vs. 56%, p=0.20), 5-year cancer-specific survival (69 vs. 67 vs. 53%, p=0.34), and 5-year overall survival (62 vs. 59 vs. 49%), p=0.74. Similar observations persisted in the multivariate Cox regression model. Conclusions: There appears to be no differences in survival outcomes in patients with solitary, synchronous, or metachronous CRC. Patients who present with multiple CRC tumors should be managed similarly to those who only present with an isolated tumor.
Development of quality indicators for women at high risk for breast cancer.
Authors: Armin Shahrokni, Patrick Youngwhan Chun, Arash Naeim, Erin M. O’Leary, Antonia Petruse, Lisa Jo Keefer, Neil Wenger
Journal: Journal of Clinical Oncology (2012)

264 Background: Thousands of women are at higher risk for developing breast cancer because of personal (such as early menarche, nulliparity), familial (e.g. BRCAI and II gene mutations), or clinical risk factors (e.g. chest wall radiation). It is thought that many, if not most, of these high risk women are not currently recognized and therefore not offered approaches to risk mitigation and early diagnosis; however, there is currently no set of measures to evaluate the quality of care provided to these women. We aimed to develop valid and feasible process-of-care quality indicators (QIs) for care of women at high risk for breast cancer. Methods: 2,402 articles from 2002 to April of 2012 were found to be appropriate for our study by search on PubMed and Medline. Studies were included if they showed a relationship between care processes for the identification, detection and risk reduction of breast cancer in women at high risk of the disease. Two reviewers reviewed the abstracts and then full texts of articles, and reviewed guidelines from the American Cancer Society, US Preventive Services Task Force and the National Comprehensive Cancer Network guidelines in producing a monograph of evidence supporting proposed QIs. A multidisciplinary panel of clinicians reviewed the evidence and rated each proposed QI for validity and feasibility. They then convened for a face to face meeting to discuss disagreements and then re-rate the measures. Results: Of 36 proposed QIs, 18 QIs were judged as valid and feasible to measure quality of care provided to women at high risk of breast cancer. Four QIs focused on identification of high risk women and risk communication. Six QIs related to counseling and genetic testing. Four QIs aimed at early detection and four QIs related to risk reducing interventions. No physician intervention to change a woman’s life style was rated highly enough to be a quality of care measure. Conclusions: A set of 18 QIs for the care of women high risk for breast cancer was developed along with the supporting literature and these measures will be applied to identify whether there are areas of care in need of improvement.